Login
$INVA
$18.49 -$0.54 (2.84%) Live

$INVA 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

Innoviva Specialty Therapeutics commercial momentum continues with $43.3 million generated in U.S. net product sales, representing 45% year-over-year growth

05 Aug 2026 8-K: Results of Operations and Financial Condition

IST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth

18 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

06 May 2026 8-K: Results of Operations and Financial Condition

Generated $58.6 million in revenue from resilient royalties portfolio

04 May 2026 8-K: Submission of Matters to a Vote of Security Holders

At the Annual Meeting of Stockholders held on May 4, 2026 (the “Meeting”), the stockholders of Innoviva, Inc. (“Innoviva”) elected five members to our board of directors, each for a one-year term expiring at the annual meeting of stockho...

25 Feb 2026 8-K: Results of Operations and Financial Condition

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

05 Nov 2025 8-K: Results of Operations and Financial Condition

Generated $63.4 million in revenue from durable royalties portfolio

06 Aug 2025 8-K: Results of Operations and Financial Condition

Strong royalties portfolio performance with $67.3 million in revenue

21 May 2025 8-K: Submission of Matters to a Vote of Security Holders

At the Annual Meeting of Stockholders held on May 19, 2025 (the “Meeting”), the stockholders of Innoviva, Inc. (“Innoviva”) elected five members to our board of directors, each for a one-year term expiring at the annual meeting of stockh...

07 May 2025 8-K: Results of Operations and Financial Condition

Core royalty platform maintained strong performance, generating $61.3 million in revenue

26 Feb 2025 8-K: Results of Operations and Financial Condition

Core royalty platform continues to deliver with GSK royalties of $66.0 million for the fourth quarter and $255.6 million for the full year

06 Nov 2024 8-K: Results of Operations and Financial Condition

Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth

31 Jul 2024 8-K: Results of Operations and Financial Condition

Core royalty platform continued strong performance, receiving GSK royalties of $67.2 million

20 Jun 2024 8-K: Submission of Matters to a Vote of Security Holders

At the Annual Meeting of Stockholders held on June 17, 2024 (the “Meeting”), the stockholders of Innoviva, Inc. (“Innoviva”) elected six members to our board of directors, each for a one-year term expiring at the annual meeting of stockh...

13 May 2024 8-K: Regulation FD Disclosure

Forward - looking statements The information in this presentation contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as...

08 May 2024 8-K: Results of Operations and Financial Condition

Core royalty platform on track; receiving GSK royalties of $61.9 million

30 Apr 2024 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers

29 Feb 2024 8-K: Results of Operations and Financial Condition

Core royalty platform on track; received GSK royalties of $69.6 million for fourth quarter

06 Nov 2023 8-K: Regulation FD Disclosure

Zoliflodacin Phase 3 clinical trial topline data November 2, 2023

01 Nov 2023 8-K: Results of Operations and Financial Condition

Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support